Patents by Inventor Robert S. Andrews

Robert S. Andrews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6886251
    Abstract: A method of making steel beams in accordance with the present invention comprises sending web fabrication information to a web cutting station indicative of web sizes needed to make webs for steel beams and indicative of a web discharge sequence in which the webs are to be discharged from the cutting station. Steel plate is cut at the cutting station to form webs having the indicated web sizes. A series of the webs are transported from the cutting station to a beam station according to the web discharge sequence. Flange fabrication information is sent to a flange station indicative of flange sizes needed to make flanges for the beams and a flange discharge sequence in which the flanges are to be discharged from the flange station corresponding to the web discharge sequence. Steel stock is cut so as to form flanges having the indicated flange sizes. The flanges are transported to the beam station according to the flange discharge sequence so as to match the flanges with an associated one of the webs.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: May 3, 2005
    Assignee: VP Buildings, Inc.
    Inventor: Robert S. Andrews
  • Publication number: 20040185479
    Abstract: The present invention provides modified oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds are each prepared having a 5′-phosphate precursor which can be modulated to provide a 5′-phosphate group under selected conditions. In another embodiment of the invention the 5′-phosphate precursor is labile inside a target cell thereby providing an oligomeric compounds having a 5′-phosphate intercellularly.
    Type: Application
    Filed: January 14, 2004
    Publication date: September 23, 2004
    Inventors: Robert S. Andrews, Herb Boswell, Donna T. Ward
  • Patent number: 6452195
    Abstract: A wafer holder assembly includes first and second main structural members from which first and second wafer-holding arms extend. The first arm is secured to the main structural members by a graphite distal retaining member. The second arm is pivotally biased to a wafer-hold position by a graphite bias member. This arrangement provides a conductive path from the wafer to the assembly for inhibiting electrical discharges from the wafer during the ion implantation process. The assembly can further include additional graphite retaining members for maintaining the structural integrity of the assembly during the extreme conditions associated with SIMOX wafer processing without the need for potentially wafer-contaminating adhesives and conventional fasteners. The wafer-contacting pins at the distal end of the arms can be formed from silicon. The silicon pins can be coated with titanium nitride to enhance electrical contact with the wafer and to provide an abrasion resistant surface.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: September 17, 2002
    Assignee: Ibis Technology Corporation
    Inventors: Theodore H. Smick, Robert S. Andrews, Bernhard F. Cordts, III
  • Patent number: 6423975
    Abstract: A wafer holder assembly includes first and second main structural members from which first and second wafer-holding arms extend. The first arm is secured to the main structural members by a graphite distal retaining member. The second arm is pivotally biased to a wafer-hold position by a graphite bias member. This arrangement provides a conductive path from the wafer to the assembly for inhibiting electrical discharges from the wafer during the ion implantation process. The assembly can further include additional graphite retaining members for maintaining the structural integrity of the assembly during the extreme conditions associated with SIMOX wafer processing without the need for potentially wafer-contaminating adhesives and conventional fasteners. The wafer-contacting pins at the distal end of the arms can be formed from silicon. The silicon pins can be coated with titanium nitride to enhance electrical contact with the wafer and to provide an abrasion resistant surface.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: July 23, 2002
    Assignee: Ibis Technology, Inc.
    Inventors: Theodore H. Smick, Geoffrey Ryding, Bernhard F. Cordts, III, Robert S. Andrews
  • Patent number: 6155436
    Abstract: A wafer holder assembly includes first and second main structural members from which first and second wafer-holding arms extend. The first arm is secured to the main structural members by a graphite distal retaining member. The second arm is pivotally biased to a wafer-hold position by a graphite bias member. This arrangement provides a conductive path from the wafer to the assembly for inhibiting electrical discharges from the wafer during the ion implantation process. The assembly can further include additional graphite retaining members for maintaining the structural integrity of the assembly during the extreme conditions associated with SIMOX wafer processing without the need for potentially wafer-contaminating adhesives and conventional fasteners. The wafer-contacting pins at the distal end of the arms can be formed from silicon. The silicon pins can be coated with titanium nitride to enhance electrical contact with the wafer and to provide an abrasion resistant surface.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: December 5, 2000
    Assignee: Ibis Technology Corporation
    Inventors: Theodore H. Smick, Robert S. Andrews, Bernhard F. Cordts, III
  • Patent number: 5948903
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3-deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: September 7, 1999
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 5750692
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3-deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: May 12, 1998
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 5587470
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3- deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: August 14, 1995
    Date of Patent: December 24, 1996
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 5459243
    Abstract: For large scale preparation of pyrimidine ribonucleosides, the intermediate 2-O-methyl-(or ethyl)-1,3,5-tri-O-benzoyl-.alpha.-D-ribose can be prepared using a diazomethane (or diazoethane) reaction that is controlled via an inert solvent transferring system. This transfer system allows for large scale preparations of the pyrimidine ribonucleosides.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: October 17, 1995
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Oscar Acevedo, Bruce Ross, Robert S. Andrews, Robert Springer, Phillip D. Cook
  • Patent number: 5457191
    Abstract: This invention relates to compounds based on the 3-deazapurines ring system and to methods for making such compounds. The invention also generally relates to the field of "antisense" agents, agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The 3-deazapurine-containing compounds of this invention can be useful for modulating the activity of RNA when incorporated into oligonucleotides. Oligonucleotides and their analogs are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins and cleaving RNA in site specific fashions.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: October 10, 1995
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: P. Dan Cook, Oscar L. Acevedo, Robert S. Andrews
  • Patent number: 4601642
    Abstract: A hydraulic pressure intensifier is used to raise the pressure in an accumulator above a given input pressure. An oscillating piston provides a boost pressure while a pilot valve and a dump valve and restrictors allow the oscillating piston to move.
    Type: Grant
    Filed: October 1, 1985
    Date of Patent: July 22, 1986
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventor: Robert S. Andrews
  • Patent number: 4591442
    Abstract: A flash chromatography apparatus and method for rapid, moderate-resolution separation of organic compounds. A solvent reservoir is pressurized with a gas, forcing solvent under pressure through tubing into and through a sorbent-packed chromatography column. More than one solvent reservoir may be provided to permit mixed-solvent elution. Alternatively, instead of pressurizing the solvent with compressed air, one or more metering pumps may be used to deliver solvent to the column. The method includes introducing a sample to be eluted into the top of a flash chromatography column, beginning elution by introducing an elution solvent under pressure into the top of the column, the elution solvent comprising a first solvent and a second solvent in a ratio from 0:1 to 1:0, modifying the elution solvent by varying the ratio of the first solvent to the second solvent, and continuing elution with the modified elution solvent.
    Type: Grant
    Filed: November 26, 1984
    Date of Patent: May 27, 1986
    Assignee: Nelson Research & Development Co.
    Inventor: Robert S. Andrews